Co-delivery of Aurora-A inhibitor XY-4 and Bcl-xl siRNA enhances antitumor efficacy for melanoma therapy

References

• SiegelRLMillerKDJemalACancer statistics, 2016CA Cancer J Clin201666173026742998
   PubMed Web of Science ®Google Scholar
• TorreLABrayFSiegelRLFerlayJLortet-TieulentJJemalAGlobal cancer statistics, 2012CA Cancer J Clin20156528710825651787
   PubMed Web of Science ®Google Scholar
• Gray-SchopferVWellbrockCMaraisRMelanoma biology and new targeted therapyNature2007445713085185717314971
   PubMed Web of Science ®Google Scholar
• LapennaSGiordanoACell cycle kinases as therapeutic targets for cancerNature Rev Drug Discov20098754756619568282
   PubMed Web of Science ®Google Scholar
• VermeulenKVan BockstaeleDRBernemanZNThe cell cycle: a review of regulation, deregulation and therapeutic targets in cancerCell Prolif200336313114912814430
   PubMed Web of Science ®Google Scholar
• BertoliCSkotheimJMde BruinRAControl of cell cycle transcription during G1 and S phasesNature Rev Mol Cell Biol201314851852823877564
   PubMed Web of Science ®Google Scholar
• SherrCJBartekJCell cycle–targeted cancer therapiesAnn Rev Cancer Biol201614147
   Google Scholar
• MalumbresMBarbacidMCell cycle, CDKs and cancer: a changing paradigmNat Rev Cancer20099315316619238148
   PubMed Web of Science ®Google Scholar
• PittsTMDavisSLEckhardtSGBradshaw-PierceELTargeting nuclear kinases in cancer: development of cell cycle kinase inhibitorsPharmacol Ther2014142225826924362082
   PubMed Web of Science ®Google Scholar
• PeyressatreMPrévelCPelleranoMMorrisMCTargeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitorsCancers20157117923725625291
   PubMed Web of Science ®Google Scholar
• BonifácioBVda SilvaPBdos Santos RamosMANegriKMSBauabTMChorilliMNanotechnology-based drug delivery systems and herbal medicines: a reviewInt J Nanomedicine20149115
   PubMed Web of Science ®Google Scholar
• NikonovaASAstsaturovISerebriiskiiIGDunbrackRLGolemisEAAurora A kinase (AURKA) in normal and pathological cell divisionCell Mol Life Sci201370466168722864622
   PubMed Web of Science ®Google Scholar
• HirotaTKunitokuNSasayamaTAurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cellsCell2003114558559813678582
   PubMed Web of Science ®Google Scholar
• GuJGongYHuangMLuCSpitzMRWuXPolymorphisms of STK15 (Aurora-A) gene and lung cancer risk in CaucasiansCarcinogenesis200728235035516926177
   PubMed Web of Science ®Google Scholar
• SakakuraCHagiwaraAYasuokaRTumour-amplified kinase BTAK is amplified and overexpressed in gastric cancers with possible involvement in aneuploid formationBr J Cancer200184682483111259099
   PubMed Web of Science ®Google Scholar
• DarAAGoffLWMajidSBerlinJEl-RifaiWAurora kinase inhibitors- rising stars in cancer therapeutics?Mol Cancer Ther20109226827820124450
   PubMed Web of Science ®Google Scholar
• AnandSPenrhyn-LoweSVenkitaramanARAURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to TaxolCancer Cell200331516212559175
   PubMed Web of Science ®Google Scholar
• ShiJXuGZhuWDesign and synthesis of 1, 4, 5, 6- tetrahydropyrrolo[3,4-c] pyrazoles and pyrazolo[3,4-b] pyridines for Aurora-A kinase inhibitorsBioorg Med Chem Lett201020144273427820621733
   PubMed Web of Science ®Google Scholar
• C-MJHuFunctionalization of nanocarriers for efficient combination drug delivery [dissertation]San DiegoUniversity of California2011
   Google Scholar
• DentPTangYYacoubADaiYFisherPBGrantSCHK1 inhibitors in combination chemotherapyMol Interv201111213314021540473
   PubMedGoogle Scholar
• RussellMRLevinKRaderJCombination therapy targeting the Chk1 and Wee1 kinases shows therapeutic efficacy in neuroblastomaCancer Res201373277678423135916
   PubMed Web of Science ®Google Scholar
• ChaudhuriLVinceletteNDKohBDCHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivoHaematologica201499468869624179152
   PubMed Web of Science ®Google Scholar
• ShimomuraTHasakoSNakatsuruYMK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxelMol Cancer Ther20109115716620053775
   PubMed Web of Science ®Google Scholar
• SantoLHideshimaTCirsteaDAntimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomideClin Cancer Res201117103259327121430070
   PubMed Web of Science ®Google Scholar
• QiWCookeLSLiuXAurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphomaBiochem Pharmacol201181788189021291867
   PubMed Web of Science ®Google Scholar
• LeeJJYazanLSAbdullahCACA review on current nanomaterials and their drug conjugate for targeted breast cancer treatmentInt J Nanomedicine201712237328392694
   PubMed Web of Science ®Google Scholar
• KneidlBPellerMWinterGLindnerLHHossannMThermosensitive liposomal drug delivery systems: state of the art reviewInt J Nanomedicine201494387439825258529
   PubMed Web of Science ®Google Scholar
• MenKLiuWLiLDelivering instilled hydrophobic drug to the bladder by a cationic nanoparticle and thermo-sensitive hydrogel composite systemNanoscale20124206425643322955255
   PubMed Web of Science ®Google Scholar
• AllenTMCullisPRDrug delivery systems: entering the mainstreamScience200430356651818182215031496
   PubMed Web of Science ®Google Scholar
• SamadASultanaYAqilMLiposomal drug delivery systems: an update reviewCurr Drug Deliv20074429730517979650
   PubMedGoogle Scholar
• AllenTMCullisPRLiposomal drug delivery systems: from concept to clinical applicationsAdv Drug Deliv Rev2013651364823036225
   PubMed Web of Science ®Google Scholar
• PattniBSChupinVVTorchilinVPNew developments in liposomal drug deliveryChem Rev201511519109381096626010257
   PubMed Web of Science ®Google Scholar
• PatelNPandaSLiposome drug delivery system: a critic reviewJ Pharm Sci Biosci Res201224162194
   Google Scholar
• ChenXWangXWangYImproved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptideJ Control Release20101451172520307599
   PubMed Web of Science ®Google Scholar
• CzabotarPELesseneGStrasserAAdamsJMControl of apoptosis by the BCL-2 protein family: implications for physiology and therapyNat Rev Mol Cell Biol2014151496324355989
   PubMed Web of Science ®Google Scholar
• BalazsDAGodbeyWLiposomes for use in gene deliveryJ Drug Deliv2011201132649721490748
   PubMedGoogle Scholar
• KesharwaniPGajbhiyeVJainNKA review of nanocarriers for the delivery of small interfering RNABiomaterials201233297138715022796160
   PubMed Web of Science ®Google Scholar
• HeCTangZTianHChenXCo-delivery of chemotherapeutics and proteins for synergistic therapyAdv Drug Deliv Rev201698647626546464
   PubMed Web of Science ®Google Scholar
• KimJKimJJeongCKimWJSynergistic nanomedicine by combined gene and photothermal therapyAdv Drug Deliv Rev2016989911226748259
   PubMed Web of Science ®Google Scholar
• WeiT-YWWuP-YWuT-JAurora A and NF-κB survival pathway drive chemoresistance in acute myeloid leukemia via the TRAF-interacting protein TIFACancer Res201777249450828069801
   PubMed Web of Science ®Google Scholar
• YangTLiBQiSCo-delivery of doxorubicin and Bmi1 siRNA by folate receptor targeted liposomes exhibits enhanced anti-tumor effects in vitro and in vivoTheranostics20144111096111125285163
   PubMed Web of Science ®Google Scholar
• CellaDPetermanAHudgensSWebsterKSocinskiMAMeasuring the side effects of taxane therapy in oncologyCancer200398482283112910528
   PubMed Web of Science ®Google Scholar
• KumarSRajkumarSVThalidomide and lenalidomide in the treatment of multiple myelomaEur J Cancer200642111612162216750621
   PubMed Web of Science ®Google Scholar
• BwireRFreemanJHounFManaging the teratogenic risk of thalidomide and lenalidomide: an industry perspectiveExpert Opin Drug Saf20111013821121869
   PubMed Web of Science ®Google Scholar